As a young, dynamic and creative molecular diagnostics company, we have specialized in simple and rapid solutions for the diagnosis of severe infectious diseases in hospitalized patients. We help to combat infections effectively and detect antibiotic resistance at an early stage.
Curetis Provides Update on Unyvero LRT FDA 510(k) Submission
Curetis Provides Business and Financial Update for the First Quarter 2017
ATS - American Thoracic Society, Washington D.C., USA - May 19 to 24, 2017
SHEA - The Society for Healthcare Epidemiology of America, St. Louis, MO, USA - May 29 to 30, 2017